• November 22, 2023

  EISAI TO PRESENT LATEST DATA ON PERAMPANEL AT THE 77TH AMERICAN EPILEPSY SOCIETY (AES) ANNUAL MEETING

• November 20, 2023

  LEQEMBI® Wins Best New Drug And Clinical Advance Of The Year at The Scrip Awards 2023

• November 16, 2023

  EISAI NAMED AS “GREATEST IR IMPROVEMENT PREMIUM COMPANY” AND “BEST CONTINUAL IR EFFORTS PREMIUM COMPANY” AT THE JAPAN INVESTOR RELATIONS ASSOCIATION 30TH ANNIVERSARY COMMEMORATIVE AWARDS

• October 26, 2023

  EISAI PRESENTS NEW LEQEMBI® (LECANEMAB-IRMB) INVESTIGATIONAL SUBCUTANEOUS FORMULATION INTERIM STUDY RESULTS AND CLINICAL IMPROVEMENT DATA IN EARLIER STAGES OF EARLY ALZHEIMER’S DISEASE FROM ADDITIONAL ANALYSES OF CLARITY AD AT THE CLINICAL TRIALS ON ALZHEIMER’S DISEASE (CTAD) CONFERENCE
  INVESTIGATIONAL SUBCUTANEOUS FORMULATION CLEARS 14% MORE PLAQUE THAN IV, PHARMACOKINETICS (AUC) 11% HIGHER, AND SIMILAR ARIA RATES TO IV
  
  76% OF PATIENTS SHOWED NO DECLINE AND 60% SHOWED CLINICAL IMPROVEMENT AT 18 MONTHS IN LOW-TAU SUBPOPULATION IN ADDITIONAL ANALYSIS OF CLARITY AD
  
  DUAL-ACTING LEQEMBI SUPPORTS BRAIN NEURON FUNCTION BY REMOVING HIGHLY TOXIC PROTEINS (PROTOFIBRILS) THAT CAN CONTINUE TO CAUSE NEURONAL INJURY AND DEATH EVEN AFTER PLAQUE REMOVAL, OFFERING EARLY AD PATIENTS THE OPPORTUNITY FOR CONTINUED BENEFIT

• October 25, 2023

  LEQEMBI® (LECANEMAB-IRMB) NAMED ONE OF TIME’S BEST INVENTIONS OF 2023

View All

• November 8, 2023

  IR “Second Quarter Financial Results Briefing for the Fiscal Year Ending March 31, 2024 [Material, Webcast]”

• November 7, 2023

  IR “Second Quarter Financial Report for the Fiscal Year Ending March 31, 2024”

• November 6, 2023

  Sustainability "Lymphatic Filariasis Elimination Activities in Myanmar ー Message from a DEC Manager"

• October 27, 2023

  Sustainability "Eisai Participated in “RECYCLE TO END POLIO”, a Campaign Aiming for a Polio-Free World by Recycling PET Bottle Caps"

• October 26, 2023

  Thursday, October 26, 2023 06:25 a.m. (JST)
  CTAD Conference: Late-Breaking Symposium 4 – Lecanemab for early Alzheimer’s Disease: Long-Term Outcomes, Predictive Biomarkers, and Novel Subcutaneous Administration (Material, LIVE)

View All

• October 13, 2023

  Eisai Inc.'s U.S. Headquarters Earns Three Key Building Certifications
  Efforts Aimed to Help Sustain the Environment, Boost Employee Health & Wellness

• March 9, 2023

  Warning Against Solicitation, Fraudulent Emails, etc. that Use the Name of Eisai or Related Parties

• February 17, 2023

  EISAI SUPPORTS RELIEF EFFORTS FOR EARTHQUAKE IN TURKEY AND SYRIA

• July 15, 2022

  Notification Regarding U.S. Research and Development Subsidiary

• April 1, 2022

  Humanitarian Support to Ukraine

View All